期刊文献+

利奈唑胺治疗败血症患者致血小板减少症的发生与肾功能关系的研究 被引量:7

Relationship between occurrence of thrombocytopenia and renal function in sepsis patients with linezolid treatment
原文传递
导出
摘要 目的为探讨医院败血症患者利奈唑胺使用后血小板减少症的发生情况及其与患者肾功能之间的关系,以合理指导临床医师对利奈唑胺的合理使用。方法回顾性分析医院2009-2012年3年间采用利奈唑胺治疗的败血症患者152例发生相关血小板减少症的情况,并对所有使用利奈唑胺治疗患者的肾功能结果进行分析,应用SPSS15.0统计学软件分析处理,组间比较采用χ2检验。结果使用利奈唑胺治疗的败血症患者共152例,血小板减少患者58例,占38.2%,其中13例出现明显血小板减少;利奈唑胺相关血小板减少症患者中肾功能不全的共38例,发生率为65.5%,而未发生血小板减少的患者肾功能不全的为23例,发生率为24.5%,差异有统计学意义(χ2=10.43,P<0.05);此外血小板明显减少的患者肾功能不全的为12例,发生率高达92.3%;38例肾功能不全患者的血小板减少值为(74±43)×109/L,而20例肾功能正常患者的血小板减少值为(25±16)×109/L,差异有统计学意义(P<0.01)。结论利奈唑胺相关血小板减少症在败血症患者中发生比例较高,对肾功能不全患者在使用利奈唑胺治疗期间应严格监测血小板计数的变化。 OBJECTIVE To investigate the relationship between the occurrence of the platelet reduction and the renal function in the sepsis patients with the linezolid treatment ,so as to guide the rational use of linezolid for clinicians .METHODS Retrospective analysis was made on the occurrence of platelet reduction and the renal func-tion to the 152 cases sepsis patients after the linezolid treatment for 3 years from 2009 to 2012 .SPSS15 .0 statisti-cal software was used for analysis and treatment .The comparison between different groups adopted chi-square test .RESULTS A total of 152 sepsis patients received the linezolid treatment in 3 years in the hospital ,including 58 cases of patients with thrombocytopenia ,accounting for 38 .2% .Among them ,there were 13 cases suffered from significant thrombocytopenia .As for the results of renal function of the patients ,there were 38 cases with renal insufficiency (positive rate 65 .5% ) ,while only 23 patients without thrombocytopenia were found renal insufficiency (positive rate 24 .5% ) .The difference was significant (χ2 =10 .43 ,P&lt;0 .05) .It was also found that 12 patients with significant thrombocytopenia suffered from renal insufficiency , the positive rate as high as 92 .3% .The platelet reduction value of 38 cases of renal insufficiency patients was (74 &#177; 43) &#215; 109/L ,while the same value for 20 patients with normal renal function was only (25 &#177; 16) &#215; 109/L ,the difference was significant (P&lt;0 .01) .CONCLUSION There is a high occurrence proportion of thrombocytopenia among the patients with sepsis who have been cured by linezolid .Stricter monitoring measures should be taken on the change of platelet counts among the sepsis patients who have been cured by linezolid ,especially those with renal insufficiency .
出处 《中华医院感染学杂志》 CAS CSCD 北大核心 2014年第7期1653-1654,1690,共3页 Chinese Journal of Nosocomiology
基金 嘉兴市科技计划基金项目(2009AY2042)
关键词 利奈唑胺 血小板减少症 肾功能 Linezolid Thrombocytopenia Renal function
  • 相关文献

参考文献7

二级参考文献61

  • 1裴斐,王睿.磷霉素与替考拉宁对90株革兰阳性球菌的联合药敏研究[J].中华医院感染学杂志,2004,14(11):1282-1284. 被引量:11
  • 2张俊忠.美罗培南诱发严重血小板减少症1例[J].药物流行病学杂志,2004,13(6):350-350. 被引量:15
  • 3周颖杰.利奈唑胺治疗严重感染建议在治疗复杂患者时监测不良反应[J].中国感染与化疗杂志,2006,6(5):345-345. 被引量:17
  • 4Ntziora F, Falagas ME. Linezolid for the treatment of patients with central nervous system infection. Ann Pharmacother, 2007,41 : 296-308.
  • 5Hayden MK. Insights into the epidemiology and control of infection with vancomycin-resistant enterococci[J]. Clin Infect Dis,2001,31(4) :1058-1065.
  • 6Kohno S, Yamaguchi K, Aikawa N. Linezolid versus vanco mycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan [J]. J Antimicrob Chemother, 2007,60(6) : 1361-1369.
  • 7Lin DF,Zhang YY,Wu JF. Linezolid for the treatment of infections caused by Gram-positive pathogens in China[J]. Int J Antimicrob Agents, 2008,32 (3): 241-249.
  • 8Wilcox M, Nathwani D. Dryden M. Linezolid compared with teicoplanin for the treatment of suspected or proven Grampositive infections[J]. J Antimicrob Chemother,2004,53(2) : 335-344.
  • 9Nasraway SA,Shorr AF,Kuter DJ,et al.Linezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia:comparative analysis of linezolid and vancomycin use[J].Clin Infect Dis,2003,37:1609-1616.
  • 10Centers for Disease Control and Prevention (CDC).Staphylococcus aureus resistant to vancomycin-United States[J].MMWR Morb Mortal Wkly Rep,2002,51:565-567.

共引文献85

同被引文献75

  • 1甲氧西林耐药的金黄色葡萄球菌肺炎诊治与预防专家共识[J].中国医学前沿杂志(电子版),2013,5(1):45-50. 被引量:26
  • 2刘凌,周旭红,庞缨.不同剂量利妥昔单抗治疗原发性难治性免疫性血小板减少症的临床观察[J].中国生化药物杂志,2014,34(6):126-129. 被引量:15
  • 3都丽萍,梅丹.药源性血小板减少症的发病机制和临床表现及防治[J].药物不良反应杂志,2007,9(6):414-419. 被引量:88
  • 4Ament PW,Jamshed N,Horne JP.Linezolid:its role in the treatment of gram-positive,drug-resistant bacterial infections[J].Am Fam Physician,2002,65(4):663-670.
  • 5Adembri C,Fallani S,Cassetta MI,et al.Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients:intermittent versus continuous infusion[J].Int J Antimicrob Agents,2008,31(2):122-129.
  • 6Jungbluth GL,Welshman IR,Hopkins NK.Linezolid pharmacokinetics in pediatric patients:an overview[J].Pediatr Infect Dis J,2003,22(9Suppl):S153-157.
  • 7Cholongitas E,Georgousaki C,Spyrou S,et al.Linezolid-induced severe hyperbilirubinemia in a patient with decompensated cirrhosis[J].J Infect,2010,60(2):182-183.
  • 8Swoboda S,Ober MC,Lichtenstern C,et al.Pharmacokinetics of linezolid in septic patients with and without extended dialysis[J].Eur J Clin Pharmacol,2010,66(3):291-298.
  • 9El-Assal MI,Helmy SA.Single-dose linezolid pharmacokinetics in critically ill patients with impaired renal function especially chronic hemodialysis patients[J].Biopharm Drug Dispos,2014,35(7):405-416.
  • 10Ikuta S,Tanimura K,Yasui C,et al.Chronic liver disease increases the risk of linezolid-related thrombocytopenia in methicillin-resistant Staphylococcus aureus-infected patients after digestive surgery[J].J Infect Chemother,2011,17(3):388-391.

引证文献7

二级引证文献46

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部